{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-086470","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.311474+00:00","generated_at":"2026-06-12T11:46:23.756912+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CytoSorbents Q2 revenue $9.4M (+11% YoY); STAR-T trial enrollment complete","bullets":["Product sales rose 10% to $8.1M; product gross margins improved 700 bps to 74%.","STAR-T pivotal trial for DrugSorb-ATR completed enrollment ahead of schedule; DSMB recommended completion.","Quarterly cash burn reduced to ~$4.5M in H1 2023 from ~$11M in H1 2022.","Appointed Alexander D'Amico as CFO effective August 7, 2023; Michael Bator named Chairman.","Cash and restricted cash totaled $14.8M as of June 30, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-086470","json":"https://secwatch.observer/filing/0001104659-23-086470.json","markdown":"https://secwatch.observer/filing/0001104659-23-086470.md","text":"https://secwatch.observer/filing/0001104659-23-086470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923086470/0001104659-23-086470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923086470/tm2322460d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T11:46:23.756912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f62fb10297959208bcd6e25a146a2452e054ed43","claim":"Cytosorbents Corp reported the quarter ended June 30, 2023 results: revenue $9.4 million.","evidence_excerpt":"Q2 2023 Total Revenue was $9.4 million, an 11% increase from $8.5 million in Q2 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923086470/0001104659-23-086470-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$9.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}